Chromogranin A: a useful biomarker in castration-resistant prostate cancer.
Castration resistant prostate cancer
Chromogranin A
Neuroendocrine prostate cancer
Neuron-specific enolase
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
16
11
2022
accepted:
05
12
2022
pubmed:
18
12
2022
medline:
25
2
2023
entrez:
17
12
2022
Statut:
ppublish
Résumé
The natural history of prostate cancer (PC) almost always evolves to castration-resistant prostate cancer (CRPC) status, sometimes comprising pure or mixed neuroendocrine prostate cancers (NEPC) differentiation. In CRPC, monitoring using only prostate-specific antigen (PSA) is not optimal since neuroendocrine differentiated cells do not secrete PSA. Thus, monitoring with PSA and chromogranin A (CgA) may be useful. This review aims to evaluate evidence for the usefulness of CgA assessments during the monitoring of prostate cancer. This review was based on three recent meta-analysis concerning CgA and prostate cancer. Further data were obtained from PubMed and Embase databases by searches using keywords, including chromogranin A and prostate cancer. CgA levels remain largely unchanged during the early PC evolution. The development of NEPC is characterised by lower PSA secretion and increased CgA secretion. Data supporting the prognostic value of high CgA baseline levels for survival are contrasting and scarce. However, increasing CgA levels early during treatment of metastatic (m)CRPC suggests resistance to treatment and predicts shorter survival, particularly in men with high baseline levels of CgA levels. In men with mCRPC, the first-line chemotherapy may be more appropriate than other agents when baseline CgA levels are high. Also, increasing CgA levels during treatment may indicate disease progression and may warrant a change of therapy. CgA monitoring at baseline and regularly during mCRPC management may be useful for monitoring disease evolution. An increased CgA baseline levels and increasing CgA levels may assist physicians with choosing and modifying therapy.
Identifiants
pubmed: 36527470
doi: 10.1007/s00345-022-04248-0
pii: 10.1007/s00345-022-04248-0
pmc: PMC9947027
doi:
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Chromogranin A
0
Biomarkers
0
Biomarkers, Tumor
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
361-369Informations de copyright
© 2022. The Author(s).
Références
Pienta KJ, Bradley D (2006) Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 12:1665–1671
doi: 10.1158/1078-0432.CCR-06-0067
pubmed: 16551847
Conteduca V, Scarpi E, Salvi S, Casadio V, Lolli C, Gurioli G et al (2018) Plasma androgen receptor and serum chromogranin A in advanced prostate cancer. Sci Rep 8:15442
doi: 10.1038/s41598-018-33774-4
pubmed: 30337589
pmcid: 6194135
Aggarwal R, Romero GR, Friedl V, Weinstein A, Foye A, Huang J et al (2021) Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer. Prost Cancer Prostatic Dis 24:81–87
doi: 10.1038/s41391-020-0228-0
Vlachostergios PJ, Puca L, Beltran H (2017) Emerging variants of castration-resistant prostate cancer. Curr Oncol Rep 19:32
doi: 10.1007/s11912-017-0593-6
pubmed: 28361223
pmcid: 5479409
Rozet F, Mongiat-Artus P, Hennequin C, Beauval JB, Beuzeboc P, Cormier L, Fromont-Hankard G, Mathieu R, Ploussard G, Renard-Penna R, Brenot-Rossi I, Bruyere F, Cochet A, Crehange G, Cussenot O, Lebret T, Rebillard X, Soulié M, Brureau L, Méjean A (2020) Recommandations françaises du Comité de cancérologie de l’AFU—actualisation 2020–2022: cancer de la prostate. Assoc Française d’Urologie (AFU). https://doi.org/10.1016/S1166-7087(20)30752-1
doi: 10.1016/S1166-7087(20)30752-1
Yamada Y, Beltran H (2021) Clinical and biological features of neuroendocrine prostate cancer. Curr Oncol Rep 23:15
doi: 10.1007/s11912-020-01003-9
pubmed: 33433737
pmcid: 7990389
Vlachostergios PJ, Papandreou CN (2015) Targeting neuroendocrine prostate cancer: molecular and clinical perspectives. Front Oncol 5:6
doi: 10.3389/fonc.2015.00006
pubmed: 25699233
pmcid: 4313607
Laguerre F, Anouar Y, Montero-Hadjadje M (2020) Chromogranin A in the early steps of the neurosecretory pathway. IUBMB Life 72:524–532
doi: 10.1002/iub.2218
pubmed: 31891241
Corti A, Marcucci F, Bachetti T (2018) Circulating chromogranin A and its fragments as diagnostic and prognostic disease markers. Pflugers Arch 470:199–210
doi: 10.1007/s00424-017-2030-y
pubmed: 29018988
Mahata SK, Corti A (2019) Chromogranin A and its fragments in cardiovascular, immunometabolic, and cancer regulation. Ann N Y Acad Sci 1455:34–58
doi: 10.1111/nyas.14249
pubmed: 31588572
pmcid: 6899468
Gut P, Czarnywojtek A, Fischbach J, Baczyk M, Ziemnicka K, Wrotkowska E et al (2016) Chromogranin A—unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls. Arch Med Sci 12:1–9
doi: 10.5114/aoms.2016.57577
pubmed: 26925113
pmcid: 4754364
Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV et al (2018) Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J Clin Oncol 36:2492–2503
doi: 10.1200/JCO.2017.77.6880
pubmed: 29985747
pmcid: 6366813
Szarvas T, Csizmarik A, Fazekas T, Hüttl A, Nyirády P, Hadaschik B et al (2021) Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer. BJU Int 127:44–55
doi: 10.1111/bju.15086
pubmed: 32314509
Derlin T, Werner RA, Lafos M, Henkenberens C, von Klot CAJ, Sommerlath Sohns JM et al (2020) Neuroendocrine differentiation and response to PSMA-targeted radioligand therapy in advanced metastatic castration-resistant prostate cancer: a single-center retrospective study. J Nucl Med 61:1602–1606
doi: 10.2967/jnumed.120.241588
pubmed: 32169910
Yordanova A, Linden P, Hauser S, Feldmann G, Brossart P, Fimmers R et al (2020) The value of tumor markers in men with metastatic prostate cancer undergoing [(177) Lu]Lu-PSMA therapy. Prostate 80:17–27
doi: 10.1002/pros.23912
pubmed: 31579967
Fan L, Yang Y, Chi C, Ma X, Wang R, Gong Y et al (2019) Neuroendocrine differentiation markers guide treatment sequence selection in metastatic castration-resistant prostate cancer. Prostate 79:567–573
doi: 10.1002/pros.23762
pubmed: 30614033
Rathke H, Holland-Letz T, Mier W, Flechsig P, Mavriopoulou E, Röhrich M et al (2020) Response prediction of (177)Lu-PSMA-617 radioligand therapy using prostate-specific antigen, chromogranin A, and lactate dehydrogenase. J Nucl Med 61:689–695
doi: 10.2967/jnumed.119.231431
pubmed: 31653712
Yang K, Li T, Gao Z, Zhang W (2019) Effect of abiraterone combined with prednisone on serum CgA and NSE in metastatic castration-resistant prostate cancer without previous chemotherapy. Trop J Pharm Res 18:631–637
doi: 10.4314/tjpr.v18i3.27
Giridhar KV, Sanhueza C, Hillman DW, Alkhateeb H, Carlson R, Tan W et al (2018) Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 21:431–437
doi: 10.1038/s41391-018-0046-9
pubmed: 29858590
pmcid: 6126956
Thakur MK, Heilbrun L, Dobson K, Boerner J, Stark K, Li J et al (2018) Phase I trial of the combination of docetaxel, prednisone, and pasireotide in metastatic castrate-resistant prostate cancer. Clin Genitourin Cancer 16:e695–e703
doi: 10.1016/j.clgc.2018.01.019
pubmed: 29534939
pmcid: 6136146
Dong B, Fan L, Wang Y, Chi C, Ma X, Wang R et al (2017) Influence of abiraterone acetate on neuroendocrine differentiation in chemotherapy-naive metastatic castration-resistant prostate cancer. Prostate 77:1373–1380
doi: 10.1002/pros.23397
pubmed: 28804908
Niedworok C, Tschirdewahn S, Reis H, Lehmann N, Szücs M, Nyirády P et al (2017) Serum chromogranin A as a complementary marker for the prediction of prostate cancer-specific survival. Pathol Oncol Res 23:643–650
doi: 10.1007/s12253-016-0171-5
pubmed: 28012116
von Hardenberg J, Schwartz M, Werner T, Fuxius S, Muller M, Frangenheim T et al (2017) Prospective evaluation of neuromediator dynamics in castration-resistant prostate cancer patients during docetaxel. Anticancer Res 37:5117–5124
Fan L, Wang Y, Chi C, Pan J, Xun S, Xin Z et al (2017) Chromogranin A and neurone-specific enolase variations during the first 3 months of abiraterone therapy predict outcomes in patients with metastatic castration-resistant prostate cancer. BJU Int 120:226–232
doi: 10.1111/bju.13781
pubmed: 28107595
Heck MM, Thaler MA, Schmid SC, Seitz AK, Tauber R, Kübler H et al (2017) Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy. BJU Int 119:30–37
doi: 10.1111/bju.13493
pubmed: 27037533
Angulo JC, Redondo C, Sánchez-Chapado M, Colás B, Ropero S, López JI (2016) Survival predictors in patients with prostate adenocarcinoma with hormonal blockade. Pathol Res Pract 212:899–903
doi: 10.1016/j.prp.2016.07.012
pubmed: 27502465
Mahammedi H, Planchat E, Pouget M, Durando X, Curé H, Guy L et al (2016) The new combination docetaxel, prednisone and curcumin in patients with castration-resistant prostate cancer: a pilot phase II study. Oncology 90:69–78
doi: 10.1159/000441148
pubmed: 26771576
von Hardenberg J, Schwartz M, Werner T, Fuxius S, Müller M, Bolenz C et al (2016) Influence of abiraterone acetate on circulating neuromediators in chemotherapy-naïve castration-resistant prostate cancer. Prostate 76:613–619
doi: 10.1002/pros.23152
Burgio SL, Conteduca V, Menna C, Carretta E, Rossi L, Bianchi E et al (2014) Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone. Endocr Relat Cancer 21:487–493
doi: 10.1530/ERC-14-0071
pubmed: 24741024
Mitsui Y, Arichi N, Hiraki M, Harada Y, Yasumoto H, Shiina H (2015) Tissue chromogranin A expression during prostate cancer progression: prediction of chemosensitivity. Urol J 12:2165–2172
pubmed: 26135933
Conteduca V, Burgio SL, Menna C, Carretta E, Rossi L, Bianchi E et al (2014) Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide. Prostate 74:1691–1696
doi: 10.1002/pros.22890
pubmed: 25262981
Matei DV, Renne G, Pimentel M, Sandri MT, Zorzino L, Botteri E et al (2012) Neuroendocrine differentiation in castration-resistant prostate cancer: a systematic diagnostic attempt. Clin Genitourin Cancer 10:164–173
doi: 10.1016/j.clgc.2011.12.004
pubmed: 22401754
Fléchon A, Pouessel D, Ferlay C, Perol D, Beuzeboc P, Gravis G et al (2011) Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial. Ann Oncol 22:2476–2481
doi: 10.1093/annonc/mdr004
pubmed: 21436186
Sarkar D, Singh SK, Mandal AK, Agarwal MM, Mete UK, Kumar S et al (2010) Plasma chromogranin A: clinical implications in patients with castrate resistant prostate cancer receiving docetaxel chemotherapy. Cancer Biomark 8:81–87
doi: 10.3233/CBM-2011-0198
pubmed: 21896995
Zhang C, Qian J, Wu Y, Zhu Z, Yu W, Gong Y et al (2021) Identification of novel diagnosis biomarkers for therapy-related neuroendocrine prostate cancer. Pathol Oncol Res 27:1609968
doi: 10.3389/pore.2021.1609968
pubmed: 34646089
pmcid: 8503838
Hong P, Guo RQ, Song G, Yang KW, Zhang L, Li XS et al (2018) Prognostic role of chromogranin A in castration-resistant prostate cancer: a meta-analysis. Asian J Androl 20:561–566
doi: 10.4103/aja.aja_57_18
pubmed: 30084431
pmcid: 6219310
Liu Y, Zhao S, Wang J, Zhu Z, Luo L, Li E et al (2019) Serum neuroendocrine markers predict therapy outcome of patients with metastatic castration-resistant prostate cancer: a meta-analysis. Urol Int 102:373–384
doi: 10.1159/000495512
pubmed: 30517936
Appetecchia M, Lauretta R, Sperduti I, Gallucci M (2018) Chromogranin A as a biomarker for prostate cancer: is it actually relevant for clinical practice? Future Oncol 14:1233–1235
doi: 10.2217/fon-2018-0025
pubmed: 29712494
Culine S, El Demery M, Lamy PJ, Iborra F, Avances C, Pinguet F (2007) Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J Urol 178:844–848
doi: 10.1016/j.juro.2007.05.044
pubmed: 17631339